20.28
-0.44 (-2.12%)
| Previous Close | 20.72 |
| Open | 20.76 |
| Volume | 1,787,344 |
| Avg. Volume (3M) | 3,485,258 |
| Market Cap | 2,125,084,160 |
| Price / Earnings (Forward) | 17.12 |
| Price / Sales | 0.970 |
| Price / Book | 1.69 |
| 52 Weeks Range | |
| Earnings Date | 3 Nov 2025 |
| Profit Margin | -11.12% |
| Operating Margin (TTM) | -40.33% |
| Diluted EPS (TTM) | -2.64 |
| Quarterly Revenue Growth (YOY) | 80.20% |
| Quarterly Earnings Growth (YOY) | 248.40% |
| Total Debt/Equity (MRQ) | 118.73% |
| Current Ratio (MRQ) | 4.02 |
| Operating Cash Flow (TTM) | -547.15 M |
| Levered Free Cash Flow (TTM) | -741.26 M |
| Return on Assets (TTM) | -2.19% |
| Return on Equity (TTM) | -23.61% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Sarepta Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -3.5 |
| Insider Activity | -2.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | -1.20 |
|
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 4.42% |
| % Held by Institutions | 96.33% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 34.00 (Wedbush, 67.65%) | Buy |
| Median | 19.50 (-3.85%) | |
| Low | 5.00 (HC Wainwright & Co., -75.35%) | Sell |
| Average | 19.50 (-3.85%) | |
| Total | 1 Buy, 1 Sell | |
| Avg. Price @ Call | 21.65 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 27 Jan 2026 | 5.00 (-75.35%) | Sell | 22.17 |
| 14 Jan 2026 | 5.00 (-75.35%) | Sell | 22.80 | |
| Wedbush | 23 Jan 2026 | 34.00 (67.65%) | Buy | 21.13 |
| 09 Dec 2025 | 32.00 (57.79%) | Buy | 22.17 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BEHRENS M KATHLEEN | - | 22.17 | -6,494 | -143,972 |
| NICAISE CLAUDE | - | 21.24 | -6,780 | -144,007 |
| Aggregate Net Quantity | -13,274 | |||
| Aggregate Net Value ($) | -287,979 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 21.71 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| NICAISE CLAUDE | Director | 29 Jan 2026 | Disposed (-) | 6,780 | 21.24 | 144,007 |
| NICAISE CLAUDE | Director | 29 Jan 2026 | Option execute | 10,500 | - | - |
| BEHRENS M KATHLEEN | Director | 27 Jan 2026 | Disposed (-) | 6,494 | 22.17 | 143,972 |
| BEHRENS M KATHLEEN | Director | 27 Jan 2026 | Option execute | 10,500 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |